NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

TG Therapeutics, Inc. (TGTX) Stock Analysis

TG Therapeutics, Inc. (TGTX) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

TGTX

$55.99

−$0.73 (−1.28%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare TGTX with… →

TGTX Key Statistics

As of Sep 4, 2026
Trading
Open
$56.30
Previous Close
$56.71
Day's Range
55.56–56.70
52-Week Range
26.76–59.30
Volume
992.40K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.66
Valuation
Market Cap
$8.57B
P/E Ratio
20.43
Forward P/EShare price divided by forecast earnings for the year ahead, rather than the year just past.
18.88
PEG RatioThe P/E ratio divided by the expected earnings growth rate. It puts a high P/E in the context of how fast profits are growing.
1.61
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
10.72
EPS (ttm)Profit attributable to each share over the last twelve months.
2.74
Financials (FY)
Revenue (FY)
$616.29M+87.32%
Net Income (FY)
$447.18M+1812.41%
Profit marginThe share of revenue left as profit after all costs and taxes.
55.22%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
153.08M
1-Year Return
+75.56%
Dividend and dates
Earnings Date
November 2, 2026estimated
Avg Volume
2.47M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

TGTX Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+87.81%
2025−0.96%
2024+76.23%
2023+44.38%
2022−37.74%
2021−63.48%
2020+368.65%
2019+170.73%
2018−50.00%
2017+76.34%
2016 (partial year)−16.22%

As of September 4, 2026.

TGTX Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$616.29M$447.18M72.6%
2024$329.00M$23.38M7.1%
2023$233.66M$12.67M5.4%
2022$2.79M−$223.81M−8036.3%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$616.29M$515.57M$123.32M$447.18M72.6%
2024$329.00M$290.52M$41.93M$23.38M7.1%
2023$233.66M$219.53M$20.63M$12.67M5.4%
2022$2.79M$2.52M−$218.32M−$223.81M−8036.3%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

TGTX Valuation vs Biotechnology Median

Median of 656 stocks
MetricTGTXBiotechnology medianvs median
P/E20.4312.5763% above
P/S ratio10.7215.2630% below
Profit margin55.22%0.00%55.2 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

All 8 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values TG Therapeutics, Inc. (TGTX) at $8.57B. It is classified in the Biotechnology industry, within the Healthcare sector. Headcount on file is 399.

The 52-week range on file runs from $26.76 to $59.30. TGTX last closed at $55.99 on September 4, 2026. That is −$0.73 (−1.28%) against the previous close. The latest close sits 109.21% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $616.29M. Against the prior fiscal year total of $329.00M, that is a change of +87.32%. Net income for the same year was $447.18M. That is +1,812.41% against the prior fiscal year. The reported profit margin is 55.22%. That is 55.2 percentage points above the Biotechnology median of 0%. Trailing earnings per share are 2.74.

Across the 4 fiscal years on file, revenue moves from $2.79M in 2022 to $616.29M in 2025. Of those 4 years, 3 report positive net income.

Valuation Assessment

The trailing P/E ratio stands at 20.43. That is 62.53% above the Biotechnology median of 12.57. On forward earnings the ratio is 18.88. The PEG ratio, which sets the P/E against expected earnings growth, reads 1.61. Measured against sales, the shares trade at 10.72 times revenue. On price-to-sales that is 29.77% below the Biotechnology median of 15.26. The medians here are taken across 656 Biotechnology companies that report the metric.

The reported beta is 1.66. Daily returns over the trailing 10 years annualize to a volatility of 86.67%. Over the trailing twelve months the price has returned +75.56%. Across 10 years the annualized return works out at +23.97%.

Growth & Income

No dividend is on file for TGTX.

So far in 2026 the price is +87.81%. The strongest complete calendar year on file is 2020 at +368.65%; the weakest is 2021 at −63.48%. Of the 9 complete calendar years on file, 5 finished higher.

Peer Comparison

TG Therapeutics, Inc. (TGTX) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
TG Therapeutics, Inc. TGTX $8.57B 20.4
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. TG Therapeutics, Inc. trades at a P/E of 20.4.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About TG Therapeutics, Inc.

TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. The company provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Ublituximab IV, glycoengineered anti-CD20 mAb for the treatment of relapsing MS; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; and Jiangsu Hengrui Medicine Co. The company was incorporated in 1993 and is based in Morrisville, North Carolina.

Visit website →